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Abstract
Background:  Methicillin-resistant  Staphylococcus aureus (MRSA) has become increasingly
prevalent worldwide since it was first reported in a British hospital. The prevalence however, varies
markedly in hospitals in the same country, and from one country to another. We therefore sought
to document comprehensively the prevalence and antimicrobial susceptibility pattern of MRSA
isolates in Trinidad and Tobago.
Methods: All Staphylococcus aureus isolates encountered in routine clinical specimens received at
major hospitals in the country between 2000 and 2001 were identified morphologically and
biochemically by standard laboratory procedures including latex agglutination test (Staphaurex Plus;
Murex Diagnostics Ltd; Dartford, England); tube coagulase test with rabbit plasma (Becton,
Dickinson & Co; Sparks, MD, USA), and DNase test using DNase agar (Oxoid Ltd; Basingstoke,
Hampshire, England). MRSA screening was performed using Mueller-Hinton agar containing 6 μg
oxacillin and 4% NaCl, latex agglutination test (Denka Seiken Co. Ltd, Tokyo, Japan) and E-test
system (AB Biodisk, Solna, Sweden). Susceptibility to antimicrobial agents was determined by the
modified Kirby Bauer disc diffusion method while methicillin MICs were determined with E-test
system.
Results: Of 1,912 S. aureus isolates received, 12.8% were methicillin (oxacillin) resistant. Majority
of the isolates were recovered from wound swabs (86.9%) and the least in urine (0.4%) specimens.
Highest number of isolates was encountered in the surgical (62.3%) and the least from obstetrics
and gynaecology (1.6%) facilities respectively. Large proportions of methicillin sensitive isolates are
>85% sensitive to commonly used and available antimicrobials in the country. All MRSA isolates
were resistant to ceftriaxone, erythromycin, gentamicin and penicillin but were 100% sensitive to
vancomycin, rifampin and chloramphenicol.
Conclusion: There is a progressive increase in MRSA prevalence in the country but the present
rate is still low in comparison to values in some other countries. Vancomycin is still the drug of
choice for treating multidrug resistant MRSA infections. Further use of molecular studies to
monitor the epidemiology of MRSA in these hospitals in the country is highly recommended too.
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Background
Methicillin-resistant  Staphylococcus aureus (MRSA) has
become increasingly prevalent worldwide since it was first
reported among hospitalized patients in a British hospital
[1,2]. The prevalence of MRSA as a major cause of morbid-
ity, increased cost of healthcare delivery services and mor-
tality in hospitals has increased during the last decade [3-
5]. The prevalence of MRSA differs widely among different
countries including from one hospital to another in the
same country [6]. In the USA for instance, the prevalence
of MRSA in some areas initially used to be associated with
tertiary care referral hospitals affiliated perhaps with
teaching hospitals [7,8], but it is now present in hospitals
of all sizes [9].
In many hospitals and areas worldwide, the prevalence of
MRSA poses a serious therapeutic problem. There are lim-
ited choices of antimicrobial agents to treat many serious
life-threatening infections caused by MRSA leading to pro-
longed stay of such patients in the hospital and increased
cost of care. In Trinidad and Tobago, several independent
studies of MRSA prevalence though limited in many
aspects have been carried out in one hospital or the other
in the country. Those previous studies reported the preva-
lence of MRSA from a cross section of one hospital or
another in the country and this may not have reflected the
true picture of the general prevalence rate of MRSA exist-
ing in Trinidad & Tobago. We therefore sought to deter-
mine in a more comprehensive manner the prevalence
and antimicrobial susceptibility pattern of MRSA in three
major regional hospitals in the country.
Methods
Source of bacterial isolates and identification
Staphylococcus aureus isolates from routine clinical speci-
mens submitted at the microbiology laboratories of three
major regional hospitals (from the south, San Fernando
General Hospital SFGH; from northwest, Port of Spain
General Hospital POSGH and from north central, Eric
Williams Medical Sciences Complex, EWMSC) in the
country from January 2000 to December 2001 were
included in this study. All isolates were identified mor-
phologically and biochemically by standard laboratory
procedures [10]. No duplicate isolates from a single
patient were included. The isolates were identified using
latex agglutination test (Staphaurex Plus; Murex Diagnos-
tics Ltd; Dartford, England), tube coagulase test with rab-
bit plasma (Becton, Dickinson & Co; Sparks, MD, USA),
and DNAse test with DNAse agar plate (DNase, Oxoid
Ltd; Basingstoke, Hampshire, England).
Methicillin resistance detection
(1) Oxacillin disk diffusion tests
The entire surface of Mueller-Hinton agar (MHA) plate
containing 6 μg oxacillin and 4% NaCl was covered with
the required inoculum, and the plate was air dried before
a 1 μg disks were laid on the surface. The plates were incu-
bated in ambient air atmosphere for 18 – 24 hours at
35°C. Evidence of growth suggested that the isolates were
oxacillin resistant.
(2) MRSA-Screen latex agglutination test
The MRSA-Screen latex agglutination test (Denka Seiken
Co. Ltd, Tokyo, Japan) was performed according to the
manufacturer instructions. For each strain, a 5-μl loopful
of S. aureus colonies was obtained from fresh subculture
and was suspended in 1.5 ml micro centrifuge tube con-
taining 200 μl of extraction reagent # 1 (0.1 M NaOH).
The suspension was boiled for 3 minutes and then one
drop (50 μl) of extraction reagent #2 (0.5 N KH2PO4) was
added and mixed well. The mixture was centrifuged at
1500 × g for 5 minutes at room temperature. A 50 μl aliq-
uot of the supernatant was added to each of the two circles
on a disposable test card and mixed with one drop (25 μl)
of the anti-PBP 2a monoclonal antibody sensitized latex
and one drop (25 μl) of the negative control latex, respec-
tively. The contents on the slide were then mixed for 3
minutes on a shaker and agglutination was observed visu-
ally and was scored as positive, negative or weakly positive
(3). E – test method
Methicillin (oxacillin) MICs were determined with the E-
test strips (AB Biodisk, Solna, Sweden) using 0.5 McFar-
land inoculum according to the manufacturer's instruc-
tions. The oxacillin E-test strip was placed onto Mueller-
Hinton agar plate supplemented with 2% NaCl, and the
plate was incubated at 35°C for 24 h. Methicillin suscep-
tibility and methicillin resistance were defined as oxacillin
(OXA) E-test MICs of = 2 and = 4 μg/ml respectively. All
results were validated using quality control strains: MRSA
ATCC 43300, MSSA ATCC 25923 and S. epidermis ATCC
12228
Antimicrobial susceptibility and MIC testing
Susceptibilities to common antibiotics were determined
by modified Kirby-Bauer disk diffusion methods accord-
ing to the Clinical Laboratory Standards Institute, for-
merly NCCLS guidelines [11]. The following antibiotics
disks: ceftriaxone (30 μg), chloramphenicol (30 μg), cip-
rofloxacin (5 μg), erythromycin (15 μg), gentamicin (10
μg), meropenem (10 μg), oxacillin (1 μg), penicillin (10
u), tetracycline (30 μg), trimethoprim-sulphamethaoxa-
zole (1.25/23.75 or 25 μg), rifampin (10 μg) and vanco-
mycin (30 μg); all from Oxoid (Oxoid Ltd; Basingstoke,
Hampshire, England) were tested. The MICs of the iso-
lates were confirmed with the E-test methods as above.
Parameters such as increasing inoculum, prolonged incu-
bation from 18 hours – 24 hours, growth at low tempera-
ture of 35°C and oxacillin screen test with NaCl wereAnnals of Clinical Microbiology and Antimicrobials 2006, 5:16 http://www.ann-clinmicrob.com/content/5/1/16
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employed in certain cases to improve sensitivity or specif-
icity for the tests methods. All tests gave satisfactory results
with the reference strains.
Results
A total of 1912 Staphylococcus aureus isolates were received
from the three major hospitals. The performance of all
three tests methods used to detect (screen) methicillin
resistance in the Staphylococcus aureus isolates revealed
very satisfactory results. Oxacillin disk diffusion and Latex
agglutination methods compared excellently well with the
E-test methods which provided a very rapid method for
measuring the MICs for all the S. aureus isolates. All tests
methods had 100% sensitivity and specificity for all iso-
lates identified as MRSA or methicillin sensitive S. aureus
(MSSA).
Results of specimen source and distribution of the MRSA
isolates in the different facility of the three major hospitals
in Trinidad & Tobago are depicted in Tables 1 &2. Half
(50%) of the MRSA isolates were from the San Fernando
General hospital. Majority of the isolates were recovered
from wound swabs (86.9%) and the surgical facility
(62.3%) of each hospital while the least were from urine
(0.4%) and the obstetrics and gynaecology (1.6%) facil-
ity. There was no significant difference in the gender dis-
tribution of the S. aureus isolates in terms of their
susceptibility to methicillin. Among the MSSA isolates
male patients accounted for 49% (817/1668) while it was
51% (851/1668) for females; and for MRSA isolates it was
49.6% (121/244) for males and 50.4% (123/244) for
females.
The E-test oxacillin tests revealed that 87.2% (1668/1912)
of the isolates had MICs of <2 mg/ml, 1.8% (34/1912)
had values >64 mg/ml and 11% (210/1912) were >256
mg/ml; and oxacillin resistance (MICs = 2 mg/ml) rate of
12.8% was obtained. The antibiotic susceptibility data for
all the S. aureus isolates are depicted on Table 3. Large pro-
portions of MSSA isolates were still over 85% sensitive to
several antimicrobial agents available and readily used in
the country.
All the MRSA isolates were resistant to ceftriaxone, eryth-
romycin and gentamicin, but were 100% sensitive to van-
comycin, rifampicin and chloramphenicol. No antibiotic
resistance pattern was found to be specific to any particu-
lar ward (data not shown)
Discussion
In this study, the prevalence of methicillin resistant Sta-
phylococcus aureus was found to be 12.8% from three
major regional hospitals in Trinidad and Tobago. This
prevalence is higher than previous rates, 0.7% in 1992–
1993; 4.8% in 1995–1996 and 9.8% in 1997–1998 that
had been reported in the country [12-15]. This 12.8%
prevalence rate found in this study is exactly the same rate
found in a pan-European data on methicillin-resistant
Staphylococcus aureus (MRSA) that was obtained from
studies conducted among 43 laboratories from 10 Euro-
pean countries [16]. However, in other countries such as
Portugal and Italy, the prevalence was over 50%; England,
Greece and France 25%, while the Netherlands and Swit-
zerland had the lowest 2% [17]. Among Western Pacific
countries, percentages of MRSA strains ranged from
23.6% in Australia to over 61% in Taiwan and Singapore,
and more than 70% in Japan and Hong Kong [18]
This increase of MRSA prevalence found in this study
when compared to previous reports in the country may be
due to several factors – the length of study period, number
of study sites and the sample size. Data from previous
research were from only one hospital in the country, were
conducted in less than 24 months, and had lower amount
of specimens giving isolates of Staphylococcus aureus. This
study was however not designed to identify risk factors for
MRSA prevalence but in a country where prevalence is
low, this has been associated with restriction of antibiotic
use, strict infection control measures and high ratio of
nurses to patients [19]. All these do not exist in these
major hospitals in Trinidad & Tobago and could have
contributed to the high MRSA prevalence rate during this
period of study. This 12.8% prevalence rate in this country
is still low compared to rates in the USA or some other
countries, and the reason why there may be a progression
Table 1: Specimen source distribution of MRSA clinical isolates from three major hospitals in Trinidad & Tobago, 2000 – 2001
Hospital N Specimen source of MRSA isolate (%)
Blood W/swabs Sputum Eye swab Urine others
POSGH 117(48) 2 105 3 2 1 4
E W M S C 6 ( 2 ) 060000
SFGH 121(50) 2 101 3 3 0 12
Total 244 4(1.6) 212(86.9) 6(2.5) 5(2.0) 1(0.4) 16(6.6)
N = total number of isolates; W/swabs = wound swabs; POSGH = Port of Spain General Hospital; EWMSC = Eric Williams Medical Science 
Complex; SFGH = San Fernando General Hospital; Others = tubes and fluid types specimensAnnals of Clinical Microbiology and Antimicrobials 2006, 5:16 http://www.ann-clinmicrob.com/content/5/1/16
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of MRSA prevalence in the country is not clear and
requires further study. In a study conducted elsewhere, a
rise in MRSA infections was associated with epidemics in
large teaching hospitals which later spread to other areas
[20]. There has not been any reported case of MRSA out-
break in these regional hospitals in Trinidad & Tobago.
Prevalence of MRSA in this country as a whole did not
vary significantly by gender in this study, and this is in
agreement with earlier reports by Saravolatz et al and
Charlebois et al [21,22]. These authors have reported that
gender was not identified to be a risk factor for the acqui-
sition or colonization of MRSA. In this study however
there was a significant difference between the prevalence
of methicillin-resistant Staphylococcus aureus and methicil-
lin sensitive Staphylococcus aureus in both males and
females. In a study by Osmon et al, they found no differ-
ence in the prevalence of MRSA and MSSA isolates from
the cases they studied [23]. No obvious reason has been
reported in literature as to the impact of gender in the
prevalence of methicillin resistant or sensitive Staphylococ-
cus aureus in the community or hospital settings. The
probable reason for no difference in gender prevalence of
Staphylococcus aureus in this study may be population
characteristics, with approximately same number of males
and females presenting in any particular area with infec-
tions. In this our study, at the EWMSC for example, more
female patients were seen with MRSA because more
females were equally seen at that hospital.
The highest prevalent rates of MRSA isolates were encoun-
tered in wound swabs specimens and the surgical wards of
the hospitals in this study. These findings are also in
agreement with result in Canada by Simor et al, where
most of the patients with MRSA were older adults receiv-
ing care on medical or surgical units [24]; and also in a
study by Müller-Premru and Gubina, where MRSA epi-
demic occurred in a surgical unit of a hospital [25]. The
pattern still has not changed because earlier report by
Swanston also noted more MRSA isolates coming from
the surgical ward because of high usage of antibiotics in
this facility [13]. Methicillin resistant Staphylococcus aureus
infection on surgical wards is becoming increasingly com-
mon especially in critically ill patients who have spent
prolonged periods on the intensive care unit [16]. This
study was however not designed to identify risk factors for
Table 3: Antibiotic susceptibility pattern of 1912 Staphylococcus aureus isolates from clinical specimens received at three major 
regional hospitals in Trinidad & Tobago, 2000–2001 (%)
Antimicrobial Percent of isolates sensitive
MSSA isolates, n = 1668 (87.2) MRSA isolates, n = 244 (12.8)
Penicillin 86.2 0
Ceftriaxone 87.0 0
98.8 98.8 100
Ciprofloxacin 88.0 13.9
Oxacillin 87.5 0
Erythromycin 85.6 0
Gentamicin 87.6 0
Meropenem 91.3 13.9
Tetracycline 85.7 13.9
Trimethoprim/Sulphamethazole 87.0 13.9
Rifampin 100 100
Vancomycin 100 100
n = total number of the isolates; MSSA = methicillin sensitive S. aureus; MRSA = methicillin resistant S. aureus
Table 2: Facility distribution of MRSA isolates from three major regional hospitals in Trinidad & Tobago, 2000–2001.
Hospital facility from which MRSA was isolated (%)
Surgery medicine paediatrics ICU O&G outpatient
P O S G H 6 5 3 4 3816
E W M S C 302001
S F G H 8 4 1 1 1 5 731
Total 152(62.3) 45(18.5) 20(8.2) 15(6.1) 4(1.6) 8(3.3)
ICU = Intensive Care Unit; Outpatient = includes isolates from patients coming from outpatient clinics, district health centers, private GPs and 
office; O & G = Obstetrics and GynecologyAnnals of Clinical Microbiology and Antimicrobials 2006, 5:16 http://www.ann-clinmicrob.com/content/5/1/16
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MRSA acquisition, but risk factors that have previously
been associated with acquisition of MRSA in hospitals
have also included broad-spectrum antimicrobial ther-
apy, admission to an intensive care unit, older age and
proximity to other patients with MRSA [26-28].
All MRSA isolates encountered in this study were com-
pletely resistant to antibiotics such as penicillin, oxacillin,
ceftriaxone, gentamicin and erythromycin. A similar result
was noted for penicillin and oxacillin among MRSA
strains from some other Latin American countries: thus
Brazil (penicillin), Chile (penicillin, oxacillin), Mexico
(penicillin, oxacillin) [29]. There is now an increase in
resistance pattern for erythromycin and gentamicin
because earlier report by Orrett noted that MRSA resist-
ance occurred in less than 70% of the MRSA isolates for
these two antimicrobial agents in 1997–1998 [14]. A
probably reason for this sustained increase may be due to
increase in admission population and perhaps poor infec-
tion control measures. Again, this is still an issue that will
require further study since this study was not designed to
check for reason for increase in antibiotics resistance.
There seems to be a steady rise of MRSA isolates resistance
to commonly used antibiotics in the country but fortu-
nately there has been no report of vancomycin resistance.
All MRSA isolates in this study were completely sensitive
to chloramphenicol, rifampin and vancomycin. A similar
result was obtained for vancomycin in previous reports in
Trinidad [13,14,30], and MRSA isolates from Argentina,
Brazil, Chile, Mexico and Uruguay from 1996 to 1998
were sensitive to vancomycin too [29]. Diekema DJ et al
have reported that most MRSA strains are resistant to most
other antibiotics, thereby necessitating the use of glyco-
peptide antibiotics, such as vancomycin [18]. The result of
this is treatment failures caused by some strains with
decreased susceptibility to vancomycin (vancomycin
intermediate S. aureus, VISA) that has been reported in
Japan and the United States [31,32]. With reports of van-
comycin reduced susceptibility and resistance reported
elsewhere [33-36], it is imperative that prudent use of van-
comycin be restricted to those cases in which it is abso-
lutely necessary, and a continuous surveillance of MRSA
activity on vancomycin be carried out regularly in these
hospitals in Trinidad. A report from Jamaica indicates that
there is no vancomycin resistance in a tertiary hospital
there and this is because there is antibiotics (including
vancomycin) policy in that institution [37].
The limitation to this study included the lack of knowl-
edge of some risk factors associated with incidence and
prevalence of MRSA infections in these hospitals
Conclusion
There seems to be a progressive increase in MRSA preva-
lence in the country, however, the rate in the country is
low in comparison to the rate in some other countries.
Vancomycin is still the drug of choice for treating multid-
rug resistant MRSA infections. To combat this progressive
MRSA prevalence trend in these hospitals, a regular sur-
veillance of hospital associated infection, monitoring of
antibiotic susceptibility pattern and formulation of defi-
nite antibiotic policy may be helpful. Further use of
molecular studies to monitor the epidemiology of MRSA
in these hospitals in the country is highly recommended
too.
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